Skip to main content
NanoGroup S.A. logo

NanoGroup S.A. — Investor Relations & Filings

Ticker · NNG ISIN · PLNNGRP00011 LEI · 259400HXWEAZUWRLY648 WAR Professional, scientific and technical activities
Open in API
Filings indexed 981 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country PL Poland
Listing WAR NNG

About NanoGroup S.A.

https://en.nanogroup.eu/

NanoGroup S.A. is a biotechnology company specializing in the application of nanotechnology to medicine. The company focuses on developing and licensing early-stage, pre-clinical, and Investigational New Drug (IND) solutions. Its research and development activities are concentrated on addressing critical medical needs, primarily in the fields of oncology and transplantology. Key areas of interest include innovative anticancer therapies utilizing RNA, regenerative medicine, early diagnostics, and the development of advanced organ perfusion systems for transplantation.

Recent filings

Filing Released Lang Actions
Raport 2026Q1
Interim / Quarterly Report Classification · 99% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains a full set of condensed consolidated financial statements, selected financial data for the quarter, notes, management commentary, and other required disclosures for a quarterly period. It is not merely an announcement or a certification but the actual interim (quarterly) report. Therefore, it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Polish
Raport 2026Q1
Interim / Quarterly Report Classification · 95% confidence The document is titled “Sprawozdanie Grupy Kapitałowej NanoGroup S.A. za I kwartał 2026” and contains detailed condensed consolidated interim financial statements (selected financial data, balance sheet, profit and loss, cash flows), notes, management discussion (“Zwięzły opis”), governance items, and a management statement. It is a comprehensive quarterly report for Q1 2026, not merely an announcement or press release. Therefore it matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-14 Polish
Zawarcie przez spółkę zależną od NanoGroup S.A. umów na skalowanie, optymalizację procesu wytwarzania oraz produkcję płynu NanOX 4 Kidney w standardzie jakościowym - Content (PL)
Regulatory Filings Classification · 88% confidence The document is a Polish current report type disclosure (“raport bieżący”) informing the market that a subsidiary has entered into contracts for industrial development of their NanOX 4 Kidney technology. It is neither a full financial report nor a management presentation, earnings release, nor M&A or share transaction notice. It does not contain actual financial statements but rather is a general company announcement required by the regulator. Therefore, it falls into the general Regulatory Filings category (RNS).
2026-05-13 Polish
Uzyskanie przez spółkę zależną od NanoGroup S.A. patentu w Indiach - Content (PL)
Regulatory Filings
2026-05-06 Polish
Rezygnacja Członka Rady Nadzorczej - Content (PL)
Board/Management Information Classification · 90% confidence The document announces the resignation of a supervisory board member of NanoGroup S.A., which is a change in the company’s board composition. This fits the definition of a Board/Management Information filing (MANG).
2026-04-23 Polish
Sprawozdanie z badania Skonsolidowanego Sprawozdania Finansowego - podpisy
Regulatory Filings
2026-04-23 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.